CHINO HILLS, CALIFORNIA — September 15, 2025 — Leads & Copy — SOHM, Inc. (OTCID:SHMN) has announced that the South Korea Patent Office has approved its patent application No. 10-2024-7041475 for its “CAS9 Retroviral Integrase and CAS9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism” technology.
According to Dr. David Aguilar, this patent builds on SOHM’s global IP portfolio around the ABBIE gene-editing platform, which fuses dCas9 with retroviral integrases.
The allowance from the Korean office reinforces ABBIE’s potential as a solution for site-specific integration, a step toward developing allogeneic CAR-T therapies and regenerative medicine, according to SOHM.
SOHM remains focused on building a global intellectual property estate to secure its innovations and drive partnerships.
Baron Night, CEO/Dr. David Aguilar, COO, Email: info@sohm.com, Phone: (714) 522-6700
Source: SOHM, Inc.
